Changing Organizational Beliefs Of State Funded Research Universities At The Age Of Big Business

4. Robert Langer, a faculty member at MIT 's prestigious Whitehead Institute, is mentioned in the article. He is a member of the Scientific Advisory Board of In Vivo Therapeutics and has a long list of accomplishments. As a faculty member should he or others who are full time faculty members at any university or college have constraints on their contributions to and activity with biotechnology companies? How might you design a fair strategic plan that would allow university research faculty to translate their work into new medical devices or practices that have both commercial and medical potential?

Biotech companies’ values are primarily driven by intellectual property, they do not need to rely much on their suppliers. These companies also have relatively easy access to sources of raw materials (such as chemicals), scientific tools, computers and testing equipment.

"We believe this organization is the most open, frank, sincere and unbiased group on the campus and to have it continue is our ideal. We know no party lines, we harbor no petty jealousies, we tolerate the indifferent, back the worker, abhor the knocker, and idolize the person who shows that he has the welfare of the University at heart. We idolize him because he possesses these admirable qualities and it matters not to us how he demonstrates it. "In order to keep abreast with the remarkable growth of the school, we believe that the time is ripe for some changes and reforms to take place within the institution but safety and substantial progress does not lie in hysteria and agitation, so we advocate a sane and intelligent appreciation and knowledge of our existing laws, traditions and customs before attempting to improve what now exists. But having a respect for our existing habits and customs that border on veneration, we still believe that academics, athletics, and social conditions can be materially bettered by whole-hearted support and cooperation to the entire University personnel.” (Arizona Daily Wildcat)

Albritton, T. J. (2012). Educating our own: The historical legacy of HBCUs and their relevance for educating a new generation of leaders.

Improvements in health care and life sciences are an important source of gains in health and longevity globally. The development of innovative pharmaceutical products plays a critical role in ensuring these continued gains. To encourage the continued development of new drugs, economic incentives are essential. These incentives are principally provided through direct and indirect government funding, intellectual property laws, and other policies that favor innovation. Without such incentives, private corporations, which bring to market the vast majority of new drugs, would be less able to assume the risks and costs necessary to continue their research and development (R&D). In the United States, government action has focused on creating the environment that would best encourage further innovation and yield a constant flow of new and innovative medicines to the market. The goal has been to ensure that consumers would benefit both from technological breakthroughs and the competition that further innovation generates. The United States also relies on a strong generic pharmaceutical industry to create added competitive pressure to lower drug prices. Recent action by the Administration and Congress has accelerated the flow of generic medicines to the market for precisely that reason. By contrast, in the Organization for Economic Cooperation and

The agreement states Pharmagen will receive up to $500 million funding for R&D costs as they are incurred solely for the research efforts of a potential new drug “X”

One of the largest obstacles hampering research is funding. There is obviously a massive amount of research that must be conducted; the

There are several rewards to consider with expansion of Biocon. Currently in India, there is a growing market for contract research organization and the growth of Biocon falls right within this opportunity. The growth is expected to last for more than few years with a rate that looks promising. Clinigene is expected to reap revenues much higher than the current Biocon and Syngene combined (Kalegaonkar A., Nov 4, 2008). It will take clinical studies to a higher level with better options in terms of drug manufacturing. With other countries ready to outsource the service of clinical studies, Clinigene’s future looks bright.

Life Science Nation (LSN) and Johnson & Johnson Innovation, JLABS (JLABS) invite fundraising life science companies to attend the upcoming Redefining Early Stage Investments (RESI) Conference in Boston on September 16th.

Students should see that the risks of the biotech business are driving all of MoGen’s financial decisions: debt policy, dividend policy, and share repurchase program. Debt is relatively low because higher debt levels would result in debt rating decreases and therefore higher interest rates. Similarly, the company chooses to pay no dividends because of the risk of being forced to cut the dividend during the difficult times that invariably arise in a biotech business. Students should realize that a share repurchase program is a very good match for a biotech company like MoGen. The company can distribute cash to its shareholders when profits allow, but without making an explicit (debt) or implicit (dividends) promise to the market.

EXECUTIVE SUMMARYSilicon Valley Medical Technologies (SIVMED) was founded as a research and development firm. In the beginning, SIVMED performed its own basic research, obtained patents on promising technologies, and then either sold or licensed the technologies to other firms which marketed the products. The firm has since then grown and is now contracted to perform research and testing for larger genetic engineering firms, biotechnology firms, the US government, and is now widely recognized as the leader in an emerging growth industry. SIVMED's founders were relatively wealthy individuals when they started company, and they committed a great deal of their own funds to the venture. Their personal funds, however, were soon exhausted by the

All researchers were paid by either BI or Eli Lilly for either consulting or data monitoring

But researchers are notoriously difficult to manage. A strategic plan cannot force a research breakthrough. Within Amgen therefore 20% of the researchers’ time is free to use as they themselves see fit.

Because of the interesting and innovative research findings with high commercial value and sustainability, my research has strong funding potential. My research has some unique criteria, (1) most of findings are patentable; (2) all products are organic; (3) applying biological process for the first time to reduce greenhouse gases; (3) applying new technologies to use CO2 and other greenhouse gases as a beneficial materials for the first time to produce new products; (4) producing new high nutrient rich organic fertilizers and pesticides, which ultimately protect the environment by eliminating the harmful contamination from water, land and soils. I have been successful at accumulating funding from both internal and

Investments by large chemical companies are focused on biobased facilities, but production credits and financing incentives are needed to create U.S.-based facilities. After a somewhat rocky start following the expiration of funding from the 2008 Farm Bill, the biobased products programs had a good level of support in the 2014 Farm Bill. The administrative regulatory rules are well developed, particularly for the Biorefinery Assistance program. Previously, this rule was strictly for advanced biofuels, whereas the current iteration expanded the sector to include biobased products and renewable chemicals. This has led to the development of a framework for assessing the biobased economy. However, this framework also requires that we make the public and private sectors be made aware of the fact that biobased products are not in stand-alone facilities; rather, they are part of a large supply chain that begins with biorefineries. In the past, if a biorefinery produced anything other than biofuels, it did not qualify for Farm Bill benefits, but this has changed.